Health and Science Technology Commercialization
Speeding Innovation From Lab to Market
Science and technology innovation is helping solve our most challenging health problems. To rapidly move a solution from idea to impact, we help public and private partners navigate funding hurdles and technical challenges—such as regulatory requirements, market access, and clinical utility—speeding up these processes from years to months. We have nearly three decades of expertise in bringing innovative technology solutions to Americans through funding, training, investments, and network support.
We help innovation happen now.
Our Services and Impact
Impact By the Numbers
- 250+ funded innovators
- 7 billion COVID-19 tests produced
- 5 months from clinical trial start to market for first rapid hepatitis C test
- $124 million in women’s health funding facilitated
We use our expertise in government funding and contract management, as well as our extensive networks, to provide the infrastructure to support new technologies. We provide award management support, negotiating, executing, and managing awards to qualified innovators and entrepreneurs, and help them move closer to commercialization.
Our services include:
- Digital health
- Analytical and bench testing
- Tissue engineering and biomaterials
- Medtech, including wearables and apps
- Diagnostics (IVDs)
- Human subjects research (HSR)
- Pre-clinical models
- Accessibility
- Design thinking
- Broadening perspectives
- Quantitative/data science
- Sustainability in design
- Intellectual property
- Technology transfer / licensing and deal negotiations
- Startup and commercialization acceleration
If you are interested in joining our expert network, explore our information for vendors and consultants.
Our Portfolio
We expand the capacity of government-funded programs in advancing solutions in a broad range of health areas, including cancer, cardiovascular disease, hepatitis B and C viruses, HIV, mpox and other lesion-causing diseases, neurodegenerative diseases, osteoarthritis, respiratory viruses (COVID-19, influenza A/B, RSV), substance use disorder, and women’s health.
RADx® Tech
The National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program works to advance diagnostic devices, wearables, and remote sensing technologies. We serve as a critical facilitator within the RADx® Tech initiatives by providing resources, networks, and support that allow medical device companies to move technologies more quickly to consumers. Our network of commercialization experts includes professionals within technical, business, regulatory, and other fields when identified by our participating companies.
We also support NIH RADx® Innovation Funnel programs, programs modeled after the RADx® Tech program, which help accelerate the commercialization of technologies to more accurately diagnose and treat infectious diseases (e.g. mpox, HIV, HBV), to improve maternal health outcomes (e.g., endometriosis), and to screen for cancer.
Blueprint MedTech
The NIH Blueprint MedTech Program aims to speed the development of cutting-edge technologies to diagnose and treat disorders of the central nervous system. On the path from lab to market, this program moves neurotechnologies from early-stage development to human-grade prototypes ready for clinical trials.
We accelerate Blueprint innovator projects by sourcing, managing, and contracting with an experienced network of vendors and consultants to both support product development and de-risk barriers to commercialization.
Investor Catalyst Hub
We manage the Advanced Research Projects Agency for Health (ARPA-H) Investor Catalyst Hub, one of three regional hubs in ARPA-H’s nationwide health innovation network.
The Investor Catalyst Hub aims to scale health research and venture investment ecosystem capabilities, disrupt traditional care models, and create new delivery pathways. Through the Investor Catalyst Hub, we support ARPA-H in navigating the complexities of the business, transition, and regulatory landscapes and provide resources to help innovators bring game-changing solutions to market to solve big problems in health. Learn more about our role.
ARPA-H employs a business model emphasizing rapid and innovative healthcare solutions and making pivotal investments in areas that cannot readily be accomplished through traditional research or commercial activity. The Investor Catalyst Hub helps accelerate the transition of new ideas into practical, accessible solutions for all Americans by connecting institutions with relevant capabilities, from incubators, accelerators, and venture investors to clinical researchers, academic institutions, and commercialization resources.
If you are interested in the ARPA-H Investor Catalyst Hub, apply to become an Investor Catalyst Hub spoke and join a nationwide network of experts from government, industry, finance, healthcare, and academia collaborating to accelerate the commercialization of groundbreaking health innovations.
Biomedical Engineering
In collaboration with the The National Institute of Biomedical Imaging and Bioengineering (NIBIB), we host the annual Design by Biomedical Undergraduate Teams (DEBUT) Challenge. The DEBUT competition awards undergraduate student teams with promising novel technologies. Teams with working prototypes are judged on impact, patentability, market potential, and innovative design.
We also support the biennial Biomedical Engineering Innovation, Design, and Entrepreneurship Alliance (BME-IDEA) Meeting and related BME-IDEA programs. This event fosters collaboration among educators, researchers, and industry leaders. We facilitate keynotes and workshops, grow the global biomedical engineering network, and support educators in integrating entrepreneurship and commercialization into biomedical engineering curricula.